We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products, contract research and development services and the manufacture of transdermal, topical and coated products. Following our acquisition of 4P Therapeutics on August 1, 2018, we are planning to develop, and seek FDA approval of, a number of transdermal pharmaceutical products under development by 4P Therapeutics.